Cargando…

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach

BACKGROUND: Intravenous augmentation therapy is the only specific treatment available for emphysema associated with alpha-1 antitrypsin deficiency. Despite large observational studies and limited interventional studies there remains controversy about the efficacy of this treatment due to the impract...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stockley, Robert A, Miravitlles, Marc, Vogelmeier, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852071/ https://www.ncbi.nlm.nih.gov/pubmed/24063809 http://dx.doi.org/10.1186/1750-1172-8-149

Ejemplares similares

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency
por: Greulich, Timm, et al.
Publicado: (2018)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency
por: Parr, David G, et al.
Publicado: (2009)

Long-term effect of α(1)-antitrypsin augmentation therapy on the decline of FEV(1) in deficient patients: an analysis of the AIR database
por: Schouten, Iris G.M., et al.
Publicado: (2021)

Cardiovascular risk in patients with alpha-1-antitrypsin deficiency
por: Fähndrich, Sebastian, et al.
Publicado: (2017)

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020)

Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group
por: Greulich, Timm, et al.
Publicado: (2022)

Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency
por: Lara, Beatriz, et al.
Publicado: (2007)

Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis
por: Barjaktarevic, Igor, et al.
Publicado: (2021)

Diagnosis of alpha-1 antitrypsin deficiency: a population-based study
por: Barrecheguren, Miriam, et al.
Publicado: (2016)

Case-finding for alpha1-antitrypsin deficiency in Kazakh patients with COPD
por: Zhumagaliyeva, Ardak, et al.
Publicado: (2017)

Application of a diagnostic algorithm for the rare deficient variant Mmalton of alpha-1-antitrypsin deficiency: a new approach
por: Belmonte, Irene, et al.
Publicado: (2016)

Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil
por: Jardim, José R, et al.
Publicado: (2021)

Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential
por: Feitosa, Paulo Henrique
Publicado: (2023)

Practice and knowledge about diagnosis and treatment of alpha-1 antitrypsin deficiency in Spain and Portugal
por: Esquinas, Cristina, et al.
Publicado: (2016)

The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency
por: Wood, Alice M, et al.
Publicado: (2008)

Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology
por: Veith, Martina, et al.
Publicado: (2019)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial
por: Campos, Michael A., et al.
Publicado: (2019)

Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency
por: Duckers, James M, et al.
Publicado: (2010)

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
por: Schmid, ST, et al.
Publicado: (2012)

Alpha-1 antitrypsin deficiency: outstanding questions and future directions
por: Torres-Durán, María, et al.
Publicado: (2018)

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank
por: Tonelli, Adriano R, et al.
Publicado: (2009)

Alpha-1 Antitrypsin Deficiency: Home Therapy
por: Annunziata, Anna, et al.
Publicado: (2021)

Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients
por: Karl, Florian M., et al.
Publicado: (2017)

There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements
por: Stockley, James A, et al.
Publicado: (2021)

Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015
por: Greulich, Timm, et al.
Publicado: (2016)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry
por: Bernhard, Nikolas, et al.
Publicado: (2017)

Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency
por: Buck, Emanuel, et al.
Publicado: (2022)

Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews
por: Miravitlles, Marc, et al.
Publicado: (2022)

Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD
por: Hampson, Judith A., et al.
Publicado: (2016)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; Methodological advances
por: Parr, David G, et al.
Publicado: (2008)

Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients ‘on’ or ‘off’ augmentation therapy
por: Olfert, I Mark, et al.
Publicado: (2014)

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry
por: Rahaghi, Franck F, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_od8pvotop6ttado66d30n30o40